STVN
NYSE · Life Sciences Tools & Services
Stevanato Group Spa
$18.23
+0.20 (+1.11%)
Financial Highlights (FY 2026)
Revenue
1.17B
Net Income
138.33M
Gross Margin
29.6%
Profit Margin
11.8%
Rev Growth
+6.4%
D/E Ratio
0.32
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 29.6% | 29.6% | 51.2% | 51.2% |
| Operating Margin | 16.8% | 15.1% | 14.1% | 13.0% |
| Profit Margin | 11.8% | 11.2% | 9.2% | 10.2% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 1.17B | 1.10B | 2.66B | 2.46B |
| Gross Profit | 347.34M | 326.33M | 1.36B | 1.26B |
| Operating Income | 196.67M | 166.29M | 376.02M | 319.21M |
| Net Income | 138.33M | 116.96M | 245.63M | 251.38M |
| Gross Margin | 29.6% | 29.6% | 51.2% | 51.2% |
| Operating Margin | 16.8% | 15.1% | 14.1% | 13.0% |
| Profit Margin | 11.8% | 11.2% | 9.2% | 10.2% |
| Rev Growth | +6.4% | +6.4% | +4.0% | +22.6% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 590.12M | 590.12M | 579.44M | 635.38M |
| Total Equity | 1.87B | 1.87B | 1.94B | 2.00B |
| D/E Ratio | 0.32 | 0.32 | 0.30 | 0.32 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | 208.88M | 186.43M | 513.68M | 453.60M |
| Free Cash Flow | — | — | 349.36M | 309.93M |